UBS Group’s Hemab Therapeutics COAG Stock Holding History

UBS Group’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Buy	+47,351	New	+$1.31M	﹤0.01%	5231

Other funds holding COAG

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's COAG Position: Q2 2026 in Review

UBS Group opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 47,351 shares worth $1.74M. The stake represents ﹤0.01% of the portfolio and ranks #5231 among its holdings.

55 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

UBS Group held 47,351 shares of Hemab Therapeutics worth $1.74M as of Q2 2026.
Hemab Therapeutics was a new UBS Group position in Q2 2026.
Hemab Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5231 holding.
55 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.